Online inquiry

IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11502MR)

This product GTTS-WQ11502MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Colorectal Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11502MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15584MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ1631MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ11772MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ3072MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ13709MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ2512MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ7730MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ14013MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW